Allergic & Contact Dermatology Services | NYU Langone Health
NYU Langone dermatologists specialize in the diagnosis and management of contact dermatitis and are expertly trained in patch testing.
ALZHEIMER S DISEASE RELATED BIOMARKERS FOLLOWING SARS-COV-2 INFECTION
A prospective, observational, longitudinal cohort study (n=300) of either: SARS-CoV-2 laboratory positive subjects who have new objective cognitive abnormalities within 12 months of SARS-CoV-2 infection (COVID+Cog+); SARS-CoV-2 laboratory positive subjects without new cognitive findings within 12 months of SARS-CoV-2 infection (COVID+Cog-); or 3) SARS-CoV-2 negative subjects who are cognitively normal (Controls). Participants will have demographic and medical history collected, along with cognitive, biomarker (plasma, MRI, digital), as well as olfactory testing approximately every 12 months over the course of 5 years.
Alzheimer’s Disease | NYU Langone Health
NYU Langone doctors diagnose people with Alzheimer’s disease and create a comprehensive plan for managing symptoms.
Alzheimer’s Disease & Related Dementias Family Support Program | NYU Langone Health
NYU Langone’s Alzheimer’s Disease and Related Dementias Family Support Program provides free services to family caregivers in New York City.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol: ATRI-001
Discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.Aim 1. Longitudinal changes in cognition and associated biomarkersDetermine and define those measures of cognition and function, including composite measures, and those biomarker measures, which capture longitudinal change with the highest statistical power to detect treatment effects in clinical trials.Longitudinal change of cerebral tau measured with 18F-AV-1451 PET (AV-1451) will be correlated/compared with other measures.Aim 2. Prediction of cognitive declineDetermine which clinical, cognitive, and biomarker measures that best predict decline of cognition in CN, MCI, and AD participants. In addition, determine which biomarker changes correlate with cognitive decline, with focus on AV-1451 PET.Aim 3. ValidationValidate biomarker measures obtained at Baseline and longitudinally by correlating results with “gold standard” clinical measurements and pathology.Aim 4. Clinical trial designDetermine the optimum outcome measures with attention to cognitive decline and AV-1451 PET, predictors of cognitive decline, and inclusion/exclusion criteria for clinical trials of cognitively normal participants (for secondary preclinical AD trials), MCI patients (for prodromal AD trials) and participants with early dementia due to AD.Aim 5. DiscoveryTo determine the effects of other known disease proteins found in AD brains and genes, as well as newly discovered genes, proteins, and analytes that provide useful information concerning the pathogenesis/diagnosis of AD.Protocol Clarifications:only those with the capacity to consent will be considered for retention in the ADNI study.
Alzheimer’s Disease Support | NYU Langone Health
NYU Langone specialists offer compassionate, supportive care for people with Alzheimer’s disease, their families, and caregivers.
Ambulatory Care Expansion | NYU Langone Health
NYU Langone’s reach is increasingly extending further into the surrounding neighborhood and region.
Ambulatory Care Pharmacy | NYU Langone Health
The pharmacists at NYU Langone’s Ambulatory Care Pharmacy make getting a prescription filled quick, easy, and convenient.
Amyloidosis Program | NYU Langone Health
Experts in the Amyloidosis Program at NYU Langone’s Perlmutter Cancer Center specialize in the diagnosis and treatment of amyloidosis.
Amyotrophic Lateral Sclerosis | NYU Langone Health
Doctors at NYU Langone provide an accurate diagnosis and ongoing support to people with ALS and their families.